A Labcorp survey of 148 US pathologists reports rising cancer rates are driving demand for digital pathology and genomic testing, but reimbursement and workforce shortages remain significant barriers to technology adoption.
SOPHiA GENETICS and AstraZeneca have signed a multi-year agreement to develop and deploy decentralized companion diagnostics for solid tumors and blood cancers, aiming to expand local lab access to precision oncology testing.
A peer-reviewed study validates Astrin Biosciences’ Certitude test, which uses proteomics and machine learning to detect early-stage breast cancer with 92.6% sensitivity and 92.3% specificity.
Researchers report that inherited CDK12 gene variants may increase risk for early, aggressive prostate cancer, suggesting inclusion of CDK12 in hereditary screening panels could improve risk identification in men.
Read More
Ibex Medical Analytics has received IVDR certification for its breast cancer diagnostic tools, completing regulatory approval for ER, PR, and Ki67 tests, according to a company press release.
Read More
The test uses intact circulating tumor cells instead of cell-free DNA fragments to analyze more than 500 genes and identify tumor markers.
Read More
The assay is designed to detect minimal residual disease with greater sensitivity than conventional flow cytometry.
Read More
A new study in The Journal of Nuclear Medicine reports that a noninvasive DNA blood test can help select advanced prostate cancer patients most likely to benefit from 223Ra radiopharmaceutical therapy and monitor treatment response.
Read More
The deal adds a blood-based test for viral-mediated cancers to the company’s portfolio of transplant and cell therapy services.
Read More
A multi-center study found that AI-assisted prostate biopsy review improved diagnostic consistency, reduced lab workloads, and cut turnaround times by nearly a day in UK NHS pathology labs.
Read More
A Kanazawa University study found that a blood-based gene expression test detected 90% of early-stage pancreatic cancer cases, outperforming CA19-9, which identified only 10%.
Read More
A3P Biomedical’s Stockholm3 test showed 90% sensitivity in detecting aggressive prostate cancer in a study of 12,670 men, outperforming traditional PSA screening.
Read More
Researchers identified coordinated lipid, metabolite, and protein signatures in symptomatic patients, supporting a multi-omic strategy for earlier ovarian cancer detection.
Read More
Spotlight Medical’s myStage Dx AI breast cancer test has received CE marking under EU IVDR, enabling adoption in European oncology and pathology labs for recurrence risk assessment in ER+/HER2- early breast cancer patients.
Read More
Freenome’s updated SimpleScreen CRC blood test met all primary and secondary endpoints in clinical validation, with improved sensitivity for precancerous lesions and colorectal cancer.
Read More
A highly sensitive blood test for KRAS mutations detected pancreatic cancer recurrence in more patients than standard methods, according to Northwestern Medicine research.
Read More
NeoGenomics has launched the first FDA-approved PTEN IHC companion diagnostic for prostate adenocarcinoma, enabling identification of patients with PTEN deficiency who may benefit from AstraZeneca’s capivasertib therapy.
Read More
The test analyzes digital biopsy images to help predict treatment response and long-term outcomes for patients with localized prostate cancer.
Read More